BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33534128)

  • 21. Presumed Pathogenic Germ Line and Somatic Variants in African American Thyroid Cancer.
    Hurst ZA; Liyanarachchi S; Brock P; He H; Nabhan F; Veloski C; Toland AE; Ringel MD; Jhiang SM
    Thyroid; 2024 Mar; 34(3):378-387. PubMed ID: 38062767
    [No Abstract]   [Full Text] [Related]  

  • 22. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
    Gosain R; Alexander JS; Gill A; Perez C
    Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coincidence of primary hyperparathyroidism and nonmedullary thyroid carcinoma.
    Lehwald N; Cupisti K; Krausch M; Ahrazoglu M; Raffel A; Knoefel WT
    Horm Metab Res; 2013 Sep; 45(9):660-3. PubMed ID: 23757116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
    Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
    Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
    Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
    J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.
    Zambeli-Ljepović A; Wang F; Dinan MA; Hyslop T; Roman SA; Sosa JA; Scheri RP
    J Surg Res; 2019 Nov; 243():189-197. PubMed ID: 31185435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
    Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
    Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
    Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
    Furuya F; Shimura H; Suzuki H; Taki K; Ohta K; Haraguchi K; Onaya T; Endo T; Kobayashi T
    Endocrinology; 2004 Jun; 145(6):2865-75. PubMed ID: 14976143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
    Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Rare Variants Predisposing to Thyroid Cancer.
    Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
    Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
    [No Abstract]   [Full Text] [Related]  

  • 39. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
    Dotinga M; Vriens D; van Velden F; Heijmen L; Nagarajah J; Hicks R; Kapiteijn E; de Geus-Oei LF
    Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):250-264. PubMed ID: 32744039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.